DK0658546T3 - 3-pyrazolcarboxamidderivater med cannabinoid-receptor-affinitet - Google Patents

3-pyrazolcarboxamidderivater med cannabinoid-receptor-affinitet

Info

Publication number
DK0658546T3
DK0658546T3 DK94402890T DK94402890T DK0658546T3 DK 0658546 T3 DK0658546 T3 DK 0658546T3 DK 94402890 T DK94402890 T DK 94402890T DK 94402890 T DK94402890 T DK 94402890T DK 0658546 T3 DK0658546 T3 DK 0658546T3
Authority
DK
Denmark
Prior art keywords
alkyl
hydrogen
nr5r6
heterocyclic radical
phenyl
Prior art date
Application number
DK94402890T
Other languages
Danish (da)
English (en)
Inventor
Christian Congy
Serge Martinez
Francis Barth
Pierre Casellas
Murielle Rinaldi
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of DK0658546T3 publication Critical patent/DK0658546T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
DK94402890T 1993-12-17 1994-12-15 3-pyrazolcarboxamidderivater med cannabinoid-receptor-affinitet DK0658546T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9315221A FR2714057B1 (fr) 1993-12-17 1993-12-17 Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
DK0658546T3 true DK0658546T3 (da) 2001-09-10

Family

ID=9454059

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94402890T DK0658546T3 (da) 1993-12-17 1994-12-15 3-pyrazolcarboxamidderivater med cannabinoid-receptor-affinitet

Country Status (11)

Country Link
US (1) US5462960A (ja)
EP (1) EP0658546B1 (ja)
JP (1) JP3825062B2 (ja)
AT (1) ATE201399T1 (ja)
DE (1) DE69427269T2 (ja)
DK (1) DK0658546T3 (ja)
ES (1) ES2159549T3 (ja)
FR (1) FR2714057B1 (ja)
GR (1) GR3036378T3 (ja)
PT (1) PT658546E (ja)
SI (1) SI0658546T1 (ja)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
DE19701277A1 (de) * 1997-01-16 1998-07-23 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
ES2213892T3 (es) * 1997-01-21 2004-09-01 Smithkline Beecham Corporation Nuevos moduladores del receptor de canabinoides.
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
JP3478268B2 (ja) * 1999-04-28 2003-12-15 東レ株式会社 カンナビノイド除去材料、カンナビノイド除去カラムおよびそれを用いたカンナビノイド除去方法
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
DE60023167T2 (de) * 1999-10-18 2006-06-14 Univ Connecticut Farmington Pyrazol-derivate als cannabinoidrezeptor-antagonisten
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
EP1361876A4 (en) * 2001-01-26 2004-03-31 Univ Connecticut NEW CANNABIMIMETIC LIGANDS
JP2005503998A (ja) 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット 受容体選択性のカンナビミメティックアミノアルキルインドール
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7057076B2 (en) * 2001-07-13 2006-06-06 University Of Connecticut Bicyclic and tricyclic cannabinoids
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
IL161439A0 (en) 2001-11-14 2004-09-27 Schering Corp Cannabinoid receptor ligands
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
EP1487436A4 (en) * 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
CA2481313A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP2005533809A (ja) 2002-06-19 2005-11-10 シェーリング　コーポレイション カンナビノイドレセプタアゴニスト
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN100486973C (zh) 2002-07-29 2009-05-13 霍夫曼-拉罗奇有限公司 新苯并间二氧杂环戊烯类
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
CA2499497A1 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
DE60328033D1 (de) 2002-11-25 2009-07-30 Schering Corp Cannabinoid-rezeptorliganden
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1583762B1 (en) 2003-01-02 2008-07-09 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
AU2003298227A1 (en) 2003-01-02 2004-07-29 F. Hoffmann-La Roche Ag Novel cb 1 receptour inverse agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
CA2522536A1 (en) * 2003-04-21 2004-11-04 Daiichi Pharmaceutical Co., Ltd. Five-membered heterocyclic derivative
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
BRPI0411699A (pt) 2003-06-20 2006-08-29 Hoffmannn La Roche Ag F compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
DE602004011394T2 (de) 2003-12-08 2009-01-08 F. Hoffmann-La Roche Ag Thiazolderivate
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
MXPA06008391A (es) 2004-01-28 2006-08-25 Hoffmann La Roche Nuevos compuestos espiro-pentaciclicos.
GB0403779D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Therapeutic agents
DE602005016082D1 (de) * 2004-02-20 2009-10-01 Astrazeneca Ab 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
JP2007536298A (ja) 2004-05-10 2007-12-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肥満を処置するためのピロールまたはイミダゾールアミド
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
ES2332416T3 (es) * 2004-06-22 2010-02-04 Schering Corporation Ligandos de receptores cannabinoides.
US8030345B2 (en) 2004-07-12 2011-10-04 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2873372B1 (fr) * 2004-07-22 2006-09-08 Sanofi Synthelabo Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
FR2874012B1 (fr) * 2004-08-09 2008-08-22 Sanofi Synthelabo Derives de pyrrole, leur preparation et leur utlisation en therapeutique
WO2006045478A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286837A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
BRPI0517653A (pt) 2004-11-09 2008-10-14 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
EP1831177A1 (en) * 2004-12-23 2007-09-12 AstraZeneca AB Therapeutic agents
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
AU2006203845A1 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP2008543912A (ja) * 2005-06-22 2008-12-04 エフ．ホフマン−ラ ロシュ アーゲー （６−フルオロ−ベンゾ［１，３］ジオキソリル）−モルホリン−４−イル−メタノンおよびｃｂ１リガンドとしてのそれらの使用
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
WO2007016771A1 (en) * 2005-08-05 2007-02-15 Uti Limited Partnership Dosing regimen for weight loss
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US20080193534A1 (en) * 2005-08-12 2008-08-14 Astrazeneca Ab Process
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007026215A1 (en) * 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
JP5069894B2 (ja) * 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
CN100999517B (zh) * 2006-01-11 2010-12-15 北京摩力克科技有限公司 吡唑甲酰胺衍生物,药物组合物和其制备方法
US7687481B2 (en) 2006-03-10 2010-03-30 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
WO2008032330A2 (en) * 2006-09-11 2008-03-20 Hetero Drugs Limited Improved process for rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
EP2097410A4 (en) 2006-09-29 2009-11-25 Green Cross Corp HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
US8431609B2 (en) 2007-02-19 2013-04-30 Darmesh Mahendrabhai Shah Process for preparation of pyrazole derivatives
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2919861A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919868A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
US8133904B2 (en) 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
CN101939022A (zh) * 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102260246B (zh) * 2010-05-28 2014-08-13 范如霖 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014219020A1 (en) 2013-02-22 2015-07-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN109952292A (zh) 2016-10-14 2019-06-28 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN110372627B (zh) * 2019-07-04 2022-12-06 南昌大学 一种1,3,4-噁二唑衍生物及其制备方法和应用
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
CN115636788A (zh) * 2022-10-31 2023-01-24 合肥工业大学 一种利莫那班n-甲基类似物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.

Also Published As

Publication number Publication date
FR2714057A1 (fr) 1995-06-23
FR2714057B1 (fr) 1996-03-08
SI0658546T1 (en) 2001-10-31
US5462960A (en) 1995-10-31
PT658546E (pt) 2001-11-30
DE69427269D1 (de) 2001-06-28
JP3825062B2 (ja) 2006-09-20
ES2159549T3 (es) 2001-10-16
DE69427269T2 (de) 2002-03-14
ATE201399T1 (de) 2001-06-15
JPH07324076A (ja) 1995-12-12
EP0658546A1 (fr) 1995-06-21
EP0658546B1 (fr) 2001-05-23
GR3036378T3 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
DK0658546T3 (da) 3-pyrazolcarboxamidderivater med cannabinoid-receptor-affinitet
AU4143893A (en) Novel pyrazole derivatives, method of preparing them and pharamceutical compositions in which they are present
SE9600683D0 (sv) Azabicyclic esters of carbamic acids useful in therapy
DK0867436T3 (da) N-arylpiperidinderivater og deres anvendelse som 5-HT1B-receptorligander
ES8701726A1 (es) Un procedimiento para la preparacion de un derivado de dihi-dropiridina
ATE212348T1 (de) Galanthamin derivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente
MX9302948A (es) Imidazolinonas fungicidas y composicion fungicida que las contiene.
DK0862562T3 (da) Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
ES2105549T3 (es) Nuevos derivados fenoxi-isobutiricos sustituidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DK0618193T3 (da) Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
AT389108B (de) Neue pyridazinonderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69329231D1 (de) Pyrazolo(4,3-c)pyridine, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Inhibitoren der Serotonin-Wiederaufnahme
DK0404359T3 (da) Dibenzothiazepin-derivater, der er nyttige som antispasmodiske midler
ATE138377T1 (de) N-(aryloxyalkyl)heteroaryl-8- azabicyclo(3.2.1>octan, zwischenverbindungen und verfahren zu deren herstellung und deren verwendung als arzneimittel
YU57287A (en) Process for obtaining estheric derivatives of 1,4-dihydropyridin-3,5-dicarboxylic acid
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
ATE250597T1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DK156396C (da) 2-(n-pyrrolidino)-3-isobutoxy-n-substituerede phenyl-n-benzyl-propylamin-forbindelser og farmaceutiske midler indeholdende disse
DK0782574T3 (da) Bicycliske carboxiamider som 5-HT1A-receptorligander
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
FI935690A (fi) Oralt aktiva antivirala foereningar
DK0573360T3 (da) Pyrrolothienopyrazinforbindelser som 5-HT3-receptorantagonister
YU110792A (sh) Supstituisani 4(5)amino-1,8-naftiridini formule i postupak za njihovu proizvodnju
ES517062A0 (es) Un metodo para la preparacion de antraniloiloxialcanoatos.